{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:50:59Z","timestamp":1774479059079,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A colo-duodenal fistula is a very rare complication of colon cancer that presents with not only severe clinical symptoms, but a poor prognosis due to locally advanced cancer. A novel immune checkpoint inhibitor for colon cancer patients provides a high objective response rate. Recently, radiation therapy combined with immune checkpoint inhibitor therapy has been reported to have a synergistic antitumor effect. A case of complete closure of a colo-duodenal fistula in a patient with locally advanced colon cancer after combined pembrolizumab and radiation therapy is reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 66-year-old man presented with abdominal distention. Abdominal contrast-enhanced computed tomography (CT) showed a 80-mm bulky mass in the right upper quadrant. The tumor created a fistula to the second portion of the duodenum. Upper gastrointestinal endoscopy showed a colo-duodenal fistula. Gastro-jejunal bypass and ileostomy were performed to prevent bowel obstruction, followed by systemic chemotherapy. MSI-high was diagnosed on examination of the biopsy specimen. Treatment was then changed to immunotherapy using pembrolizumab; after six courses, the tumor markers were decreased to within normal ranges, but the main tumor increased. Radiation therapy was then given for local control of the main tumor, after which CT showed that all of the tumor, including the main tumor, lymph node metastases, and the colo-duodenal fistula, had gradually shrunk. Follow-up upper gastrointestinal endoscopy showed that the colo-duodenal fistula had closed completely. PET\u2013CT showed no abnormal uptake in all tumors, and clinical complete response was diagnosed. Now, 21\u00a0months after diagnosis, the tumor is well controlled without evidence of regrowth.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pembrolizumab combined with radiation therapy has a potentially dramatic therapeutic effect for advanced colon cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-021-01248-x","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T07:03:41Z","timestamp":1626419021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Complete closure of a colo-duodenal fistula in a patient with advanced ascending colon cancer after pembrolizumab combined with radiation therapy: a case report"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-3227","authenticated-orcid":false,"given":"Tetsuro","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shosaburo","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nishimuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Fujise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terumitsu","family":"Sawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/0002-9610(77)90147-7","volume":"133","author":"JP Welch","year":"1977","unstructured":"Welch JP, Warshaw AL. Malignant duodenocolic fistulas. Am J Surg. 1977;133:658\u201361.","journal-title":"Am J Surg"},{"key":"1248_CR2","first-page":"476","volume":"21","author":"M Calmenson","year":"1947","unstructured":"Calmenson M, Black BM. Surgical management of carcinoma of the right portion of the colon with secondary involvement of the duodenum, including duodenocolic fistula; data on eight cases. Surgery. 1947;21:476\u201381.","journal-title":"Surgery"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13193-011-0099-x","volume":"2","author":"TA Majeed","year":"2011","unstructured":"Majeed TA, Gaurav A, Shilpa D, et al. Malignant coloduodenal fistulas-review of literature and case report. Indian J Surg Oncol. 2011;2:205\u20139.","journal-title":"Indian J Surg Oncol"},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1248_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139.","journal-title":"J Clin Oncol"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.21037\/jgo.2018.09.19","volume":"10","author":"C Wang","year":"2019","unstructured":"Wang C, Sandhu J, Fakih M. Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. J Gastrointest Oncol. 2019;10:161\u20135.","journal-title":"J Gastrointest Oncol"},{"key":"1248_CR7","first-page":"3847672","volume":"2019","author":"M Keating","year":"2019","unstructured":"Keating M, Giscombe L, Tannous T, Hartshorn K. Prolonged treatment response to pembrolizumab in a patient with pretreated metastatic colon cancer and lynch syndrome. Case Rep Oncol Med. 2019;2019:3847672.","journal-title":"Case Rep Oncol Med"},{"key":"1248_CR8","doi-asserted-by":"publisher","first-page":"e000084","DOI":"10.1136\/esmoopen-2016-000084","volume":"1","author":"M Kieler","year":"2016","unstructured":"Kieler M, Scheithauer W, Zielinski CC, et al. Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. ESMO Open. 2016;1:e000084.","journal-title":"ESMO Open"},{"key":"1248_CR9","doi-asserted-by":"publisher","first-page":"e0212978","DOI":"10.1371\/journal.pone.0212978","volume":"14","author":"T Tominaga","year":"2019","unstructured":"Tominaga T, Akiyoshi T, Yamamoto N, et al. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS ONE. 2019;14:e0212978.","journal-title":"PLoS ONE"},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1477-7819-4-86","volume":"4","author":"R Soulsby","year":"2006","unstructured":"Soulsby R, Leung E, Williams N. Malignant colo-duodenal fistula; case report and review of the literature. World J Surg Oncol. 2006;4:86.","journal-title":"World J Surg Oncol"},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1055\/s-2001-16220","volume":"33","author":"KA Pathak","year":"2001","unstructured":"Pathak KA, de Souza LJ. Duodenocolic fistula: an unusual sequela of stent migration. Endoscopy. 2001;33:731.","journal-title":"Endoscopy"},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF02587188","volume":"20","author":"TR Smith","year":"1977","unstructured":"Smith TR, Goldin RR. Radiographic and clinical sequelae of the duodenocolic anatomic relationship: two cases of Crohn\u2019s disease with fistulization to the duodenum. Dis Colon Rectum. 1977;20:257\u201362.","journal-title":"Dis Colon Rectum"},{"key":"1248_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/0002-9610(54)90561-9","volume":"87","author":"WE Neville","year":"1953","unstructured":"Neville WE. Duodenocolic fistula due to acute cholecystitis. Am J Surg. 1953;87:300\u20132.","journal-title":"Am J Surg"},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/BF02586716","volume":"21","author":"MA Ergin","year":"1978","unstructured":"Ergin MA, Alfonso A, Auda SP, Waxman M. Primary carcinoma of the duodenum producing a malignant duodenocolic fistula. Dis Colon Rectum. 1978;21:408\u201312.","journal-title":"Dis Colon Rectum"},{"key":"1248_CR15","first-page":"87","volume":"45","author":"ES Xenos","year":"1999","unstructured":"Xenos ES, Halverson JD. Duodenocolic fistula: case report and review of the literature. J Postgrad Med. 1999;45:87\u20139.","journal-title":"J Postgrad Med"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1007\/s11605-011-1630-7","volume":"15","author":"AS Kamath","year":"2011","unstructured":"Kamath AS, Iqbal CW, Pham TH, et al. Management and outcomes of primary coloduodenal fistulas. J Gastrointest Surg. 2011;15:1706\u201311.","journal-title":"J Gastrointest Surg"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104.","journal-title":"J Hematol Oncol"},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38\u201347.","journal-title":"Eur J Cancer"},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4:717\u201321.","journal-title":"JAMA Oncol"},{"key":"1248_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","volume":"36","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36:850\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-021-01248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-021-01248-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-021-01248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T07:12:05Z","timestamp":1626419525000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-021-01248-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1186\/s40792-021-01248-x","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written, informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}